Royalty Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Royalty Pharma has a total shareholder equity of $9.9B and total debt of $6.1B, which brings its debt-to-equity ratio to 62.2%. Its total assets and total liabilities are $16.1B and $6.3B respectively. Royalty Pharma's EBIT is $939.4M making its interest coverage ratio 7.7. It has cash and short-term investments of $872.0M.
Key information
62.2%
Debt to equity ratio
US$6.14b
Debt
| Interest coverage ratio | 7.7x |
| Cash | US$872.00m |
| Equity | US$9.86b |
| Total liabilities | US$6.27b |
| Total assets | US$16.13b |
Recent financial health updates
Recent updates
Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 12
Royalty Pharma: Solid Start Of The Year, Buy Confirmed
May 11Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21
Apr 28Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares
Apr 25Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?
Apr 04Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem
Feb 22Royalty Pharma: Solid Operational Performance
Feb 19Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21
Jan 31Royalty Pharma: One Of The Best Names In Pharmaceuticals
Jan 22Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion
Dec 26Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's
May 12Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20
Apr 20Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20
Jan 16Royalty Pharma to co-fund development of schizophrenia drug with Merck
Oct 12Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth
Aug 18Royalty Pharma declares $0.19 dividend
Jul 15Royalty Pharma: Unique Diversification, Bear Market Performer
May 26The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)
Apr 25Financial Position Analysis
Short Term Liabilities: RPRX's short term assets ($1.6B) exceed its short term liabilities ($124.6M).
Long Term Liabilities: RPRX's short term assets ($1.6B) do not cover its long term liabilities ($6.1B).
Debt to Equity History and Analysis
Debt Level: RPRX's net debt to equity ratio (53.4%) is considered high.
Reducing Debt: RPRX's debt to equity ratio has reduced from 130.6% to 62.2% over the past 5 years.
Debt Coverage: RPRX's debt is well covered by operating cash flow (42.7%).
Interest Coverage: RPRX's interest payments on its debt are well covered by EBIT (7.7x coverage).